Back to Search
Start Over
Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I|II Study Assessing Selective AXL Inhibitor Bemcentinib
- Source :
- Plus Company Updates. July 21, 2020
- Publication Year :
- 2020
-
Abstract
- BERGEN: BerGenBio ASA has issued the following news release: BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.630095021